Financial reports
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
7 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
30 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
Current reports
8-K
Entry into a Material Definitive Agreement
10 Apr 24
8-K
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
28 Mar 24
8-K
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of
26 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
4 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
28 Feb 24
8-K/A
Financial Statements and Exhibits
5 Feb 24
8-K
Departure of Directors or Certain Officers
23 Jan 24
8-K
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
8 Jan 24
8-K
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
27 Dec 23
Registration and prospectus
424B3
Prospectus supplement
10 Apr 24
S-3/A
Shelf registration (amended)
5 Apr 24
S-3
Shelf registration
5 Feb 24
424B5
Prospectus supplement for primary offering
21 Nov 23
425
Business combination disclosure
30 Oct 23
424B3
Prospectus supplement
10 Oct 23
S-4
Registration of securities issued in business combination transactions
28 Sep 23
425
Business combination disclosure
31 Aug 23
S-8
Registration of securities for employees
7 Mar 23
Proxies
DEFA14A
Additional proxy soliciting materials
3 Apr 24
DEF 14A
Definitive proxy
3 Apr 24
DEFA14A
Additional proxy soliciting materials
31 Aug 23
DEFA14A
Additional proxy soliciting materials
17 Apr 23
DEFA14A
Additional proxy soliciting materials
4 Apr 23
DEFA14A
Additional proxy soliciting materials
3 Apr 23
DEFA14A
Additional proxy soliciting materials
30 Mar 23
DEFA14A
Additional proxy soliciting materials
29 Mar 23
DEFA14A
Additional proxy soliciting materials
29 Mar 23
DEFA14A
Additional proxy soliciting materials
29 Mar 23
Other
EFFECT
Notice of effectiveness
9 Apr 24
EFFECT
Notice of effectiveness
11 Oct 23
CORRESP
Correspondence with SEC
6 Oct 23
UPLOAD
Letter from SEC
4 Oct 23
UPLOAD
Letter from SEC
10 Mar 23
CORRESP
Correspondence with SEC
6 Mar 23
UPLOAD
Letter from SEC
3 Mar 23
EFFECT
Notice of effectiveness
2 Feb 22
EFFECT
Notice of effectiveness
13 Jul 21
EFFECT
Notice of effectiveness
8 Jul 21
Ownership
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
4
Joshua Schafer
2 Feb 24
4
Timothy J. Sangiovanni
2 Feb 24
4
Christal M M Mickle
2 Feb 24
4
Sven Guenther
2 Feb 24
4
R. LaDuane Clifton
2 Feb 24
4
Neil F. McFarlane
2 Feb 24
4
Alvin Shih
2 Feb 24
3
Alvin Shih
2 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24